Insights On Facility Design

41. Proposed vs. Actual Cleanroom Construction Costs And Delivery Timelines 8/24/2018

    When it comes to facilities or cleanroom infrastructures in the biopharmaceutical or cell/gene therapy industry, not only does management rely on what has been promised, but also the patients. 

42. The Evolution Of Biopharmaceutical Facility Designs 8/22/2018

    In the lifecycle of pharmaceutical and biopharmaceutical commercial manufacturing, the one constant has been change. With the advent of modern therapeutics, large scale commercial manufacturing became common place.

43. Can A Shared Biomanufacturing Facility Be The Answer To The Demand Forecasting Dilemma? 8/13/2018

    Using a shared biomanufacturing facility, a biomanufacturer can minimize its investment while mitigating the risks of demand uncertainty and maximizing time to market.

44. The Top Trends Influencing Automation In The Life Science Industry 7/6/2018

    Trevor Marshall of Zenith Technologies discusses the impact that multi-product manufacturing facilities, single-use technologies, continuous manufacturing and industry 4.0 will have on automation.

45. Build Efficiency Through Continuous Characterization 2/9/2018

    Bioprocessing development is a long and costly process. Building in continuous characterization and connected bioprocessing cuts timelines and increases the available information through real-time analytics.

46. Are You Ready For The Future Of Biomanufacturing? 1/19/2018

    As novel medicines become a larger part of the industry's portfolio, it is critical you secure a supply chain and manufacturing processes that produce drugs in a reliable, cost-effective way. 

47. A Molecule’s Journey – Break Down Roadblocks To Commercial Success 1/4/2018

    A guide for today’s biopharma executives seeking to navigate through the important considerations necessary to successfully build their own cGMP biomanufacturing facility.

48. Fast-Tracking A QbD Approach 12/28/2017

    QbD starts with an understanding of the quality target product profile. This allows potential critical quality attributes (CQAs) to be established and a risk assessment performed. 

49. G-CON Gene Therapy Facility 2017 10/25/2017

    PODs provide the environments for the entire upstream and downstream process for a state of the art gene therapy facility.

50. Turnkey Facility And Cleanroom Solutions Transform Biopharma Manufacturing 10/6/2017

    Flexible and modular facility designs that can be built in a factory, shipped to the site and then rapidly assembled have been recognized and are being addressed by innovative suppliers.